Farsight Genome Systems is a leading provider of a SaaS Platform for Precision Medicine. The company has introduced an innovative SaaS solution for health systems, catering specifically to genetic/genomic testing within precision medicine programs. The API architecture seamlessly integrates with existing LIS/EMR software, offering enterprise-wide genomic data management with on-demand re-analysis and re-interpretation. Notably, end-user laboratories benefit from a selection of in silico, multi-gene Testpanels to control indication-specific analysis and reporting. The platform's capabilities are designed to accelerate the adoption of recommended genomic testing, aligning with evidence-based clinical practice guidelines. Based in the United States, Farsight Genome Systems is poised to make a significant impact in the realm of precision medicine with its cutting-edge SaaS solutions.
There is no investment information
No recent news or press coverage available for Farsight Genome Systems.